Pricing Log in Create free account

BioAge Labs, Inc. (BIOA) vs Emergent Biosolutions Inc. (EBS)

BioAge Labs, Inc. and Emergent Biosolutions Inc. are both Drug Manufacturers Specialty & Generic companies. Emergent Biosolutions Inc. is the larger, with a market value of $300.8M against $254.3M — 1.2× the size. Emergent Biosolutions Inc. has the higher net margin (−40.2% vs −1,253.6%) and the higher return on invested capital (−17.5% vs −21.8%). Across the 16 metrics below, Emergent Biosolutions Inc. leads on 9 and BioAge Labs, Inc. on 7.

Valuation

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 29.58 0.47 2.08
P/B 0.73 0.97 1.79
Price to free cash flow n/m 1.57 16.29
EV/EBITDA 0.52 n/m 12.22
EV/Sales (7.23) 0.98 2.87
Earnings yield (46.03%) (85.09%) (15.94%)
Free cash flow yield (101.34%) 63.88% 0.00%

Profitability

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 48.42% 53.51%
Operating margin (1,401.81%) (27.70%) 0.00%
Net margin (1,253.60%) (40.16%) (2.45%)
Free cash flow margin (2,997.41%) 29.89% 0.00%
Return on equity (34.56%) (58.21%) (0.80%)
Return on assets (32.05%) (21.23%) (1.67%)
Return on invested capital (21.75%) (17.45%) 0.00%

Growth

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (17.72%) 5.22%
EPS growth (last fiscal year) 66.21% 125.83% 42.91%
Revenue growth, 5-year CAGR — (13.74%) 7.24%
Net income growth, 5-year CAGR — (29.64%) 0.00%

Health

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 1.62 0.04
Current ratio 15.51 4.58 2.41
Net debt to EBITDA 3.01 1.76 1.01

Dividend

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Market cap 254.27m 300.78m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack